Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21239463 | 1.00 | FPR2 (0.57) | FPR2SMN1; SMN2TSHRALDH1A1MEN1 | |
| SCHEMBL21239484 | 1.00 | FPR2 (0.57) | FPR2SMN1; SMN2TSHRALDH1A1MEN1 | |
| SCHEMBL21239461 | 0.85 | FPR2 (0.77) | FPR2SMN1; SMN2MEN1KMT2ACNR1 | |
| SCHEMBL21239460 | 0.85 | FPR2 (0.77) | FPR2SMN1; SMN2MEN1KMT2ACNR1 | |
| SCHEMBL21239550 | 0.85 | FPR2 (0.57) | FPR2MEN1KMT2ACNR1MAPT | |
| SCHEMBL21239537 | 0.85 | FPR2 (0.77) | FPR2SMN1; SMN2MEN1KMT2ACNR1 | |
| SCHEMBL21239527 | 0.85 | FPR2 (0.57) | FPR2MEN1KMT2ACNR1MAPT | |
| SCHEMBL21239525 | 0.85 | FPR2 (0.57) | FPR2MEN1KMT2ACNR1MAPT | |
| SCHEMBL21239487 | 0.84 | POLB (0.64) | FPR2ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL29874164 | 0.84 | POLB (0.64) | FPR2ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109843283-B | Urea derivatives | 第一三共株式会社 | 2022-08-30 | — | — | CN | disclosed |
| US-20220144765-A1 | UREA DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20220144765-A1 | UREA DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20210206716-A1 | UREA DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-07-08 | — | — | US | disclosed |
| US-20210206716-A1 | UREA DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-07-08 | — | — | US | disclosed |
| US-10968169-B2 | Urea derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10968169-B2 | Urea derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| EP-3524240-A1 | UREA DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-08-14 | — | — | EP | disclosed |
| CN-109843283-A | Urea derivative | 第一三共株式会社 | 2019-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206716-A1 | UREA DERIVATIVE | IDO1, IDO2, TPH1 | FPR2 1882/4885SMN1; SMN2 4752/4885TSHR 1451/4885 |
| US-10968169-B2 | Urea derivative | IDO1, IDO2, UTS2R | FPR2 2003/4885SMN1; SMN2 4771/4885TSHR 1396/4885 |
| US-20220144765-A1 | UREA DERIVATIVE | IDO1, IDO2, TPH1 | FPR2 1882/4885SMN1; SMN2 4752/4885TSHR 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.